Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients
Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients
复制标题
快速自动检测伊马替尼耐药患者的 ABL 激酶结构域突变
DOI：
10.1016/j.canlet.2011.08.009
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
J. V.
中科院分区：
文献类型：
--
作者：
Tanaka;R.;Kimura;S.;Ashihara;E.;Yoshimura;M.;Takahashi;N.;Wakita;H.;Itoh;K.;Nishiwaki;K.;Suzuki;K.;Nagao;R.;Yao;H.;Hayashi;Y.;Satake;S.;Hirai;H.;Sawada;K-I.;Ottmann;O. G.;Melo;J. V.
ABL酪氨酸激酶抑制剂（TKI）伊马替尼用于BCR-ABL +白血病。我们建立了一种利用鸟嘌呤猝灭探针（QP）自动检测伊马替尼耐药中常见的17种突变的方法。用该方法提取100μL全血，在90min内得到结果。QP法和直接测序法检测到的突变几乎相同。此外，在QP方法中加入突变偏向PCR （MBP）以提高灵敏度，从而更早地检测到对ABL TKIs不敏感的T315I突变。因此，QP和MBP-QP可能成为ABL tki治疗患者管理的有用方法。
ABL tyrosine kinase inhibitor (TKI), imatinib is used for BCR–ABL+leukemias. We developed an automatic method utilizing guanine-quenching probes (QP) to detect 17 kinds of mutations frequently observed in imatinib-resistance. Results were obtained from 100μL of whole blood within 90min by this method. Detected mutations were almost identical between QP method and direct sequencing. Furthermore, the mutation-biased PCR (MBP) was added to the QP method to increase sensitivity, resulting earlier detection of T315I mutation which was insensitive to any ABL TKIs. Thus, the QP and MBP-QP may become useful methods for the management of ABL TKI-treated patients.